If this were the case it would be odd that this is happening a.) in a consistent subset of women 18-38
b.) that it would emerge in a 1-shot regimen rather than a 2-shot regimen, because it would seem more likely that any one individual would experience this more frequently with 2 chances for human error rather than 1
The Pfizer & Moderna 2-shot vaccines use mRNA instead of an adenovirus vector. The AZ vaccine is 2 shot, but also uses a similar adenovirus vector - the bloodclot issue has also been seen in the AZ vaccine which has led to some countries in Europe not allowing it for women under 60.
I would assume the guidelines for aspirating would be the same across all of these vaccines, though? If so the original point still stands regardless of adenovirus vs. mRNA
Yes, we know that. But what does adenovirus vs mRNA have to do with aspirating an injection? Does the adenovirus become more dangerous when accidentally placed in a blood vessel?
with only 6 people you can't really say that since it's such a tiny sample size. If it's 6 women then you're starting to get to a pattern worth testing.
